Severe long-standing dysimmune sensory neuronopathy responsive to etanercept

Journal of Clinical Neuromuscular Disease

Volumn 9, Issue 4, 2008, Pages 415-420

  Figueroa, Juan J ^a   Tabechian, Darren ^a   Herrmann, David N ^a,b  

^a UNIVERSITY OF ROCHESTER   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Dorsal root ganglionopathy; Etanercept; Inhibitor; Sensory neuronopathy; Systemic lupus erythematosus; TNF a

Indexed keywords

ANTINUCLEAR ANTIBODY; CARDIOLIPIN ANTIBODY; CYCLOPHOSPHAMIDE; ETANERCEPT; GABAPENTIN; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; RIBONUCLEOPROTEIN; SM ANTIBODY; TRAMADOL; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VENLAFAXINE; HYBRID PROTEIN; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTOR; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ALLODYNIA; ARTHRITIS; ARTICLE; ATAXIA; ATHETOSIS; CASE REPORT; CONNECTIVE TISSUE DISEASE; DEMYELINATION; DISEASE SEVERITY; DRUG RESPONSE; DYSIMMUNE SENSORY NEURONOPATHY; FEMALE; GAIT; HUMAN; IMMUNOMODULATION; JOINT STIFFNESS; LEUKOPENIA; MEDIAN NERVE; NERVE BIOPSY; NERVE CONDUCTION; NERVE FIBER DEGENERATION; NERVE POTENTIAL; NEUROLOGICAL COMPLICATION; NEUROPATHIC PAIN; NEUROPATHY; PARESTHESIA; POSITION; PRIORITY JOURNAL; PSEUDOATHETOSIS; RADIAL NERVE; SENSORY NERVE CELL; SENSORY NEUROPATHY; SKIN SENSATION; SURAL NERVE; SYSTEMIC LUPUS ERYTHEMATOSUS; TENDON REFLEX; TITRIMETRY; TREATMENT RESPONSE; ULNAR NERVE; VIBRATION; CHRONIC DISEASE; ELECTROMYOGRAPHY; IMMUNOLOGY; PATHOLOGY; PERIPHERAL NEUROPATHY; TREATMENT OUTCOME;

ADULT; ATAXIA; ATHETOSIS; CHRONIC DISEASE; ELECTROMYOGRAPHY; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; NEURAL CONDUCTION; NEURONS, AFFERENT; PARESTHESIA; PERIPHERAL NERVOUS SYSTEM DISEASES; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME;

EID: 50349088999     PISSN: 15220443     EISSN: 15371611     Source Type: Journal    
DOI: 10.1097/CND.0b013e3181659999     Document Type: Article

References (50)

1. Griffin JW, Cornblath DR, Alexander E, et al. Ataxic sensory neuropathy and dorsal root ganglionitis associated with Sjögren's syndrome. Ann Neurol. 1990;27:304-315.
2. Molina JA, Benito-Leon J, Bermejo F, et al. Intravenous immunoglobulin therapy in sensory neuropathy associated with Sjögren's syndrome. J Neurol Neurosurg Psychiatry. 1996;60:699.
3. Takahashi Y, Takata T, Hoshino M, et al. Benefit of IVIG for long-standing ataxic sensory neuronopathy with Sjögren's syndrome. Neurology. 2003;60: 503-505.
4. Pflugfelder SC, Jones D, Ji Z, et al. Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjögren's syndrome keratoconjunctivitis sicca. Curr Eye Res. 1999;19:201-211.
5. Maczynska I, Millo B, Ratajczak-Stefańska V, et al. Proinflammatory cytokine (IL-1beta, IL-6, IL-12, IL-18 and TNF-alpha) levels in sera of patients with subacute cutaneous lupus erythematosus (SCLE). Immunol Lett. 2006;102:79-82.
6. Schotte H, Willeke P, Tidow N, et al. Extended haplotype analysis reveals an association of TNF polymorphisms with susceptibility to systemic lupus erythematosus beyond HLA-DR3. Scand J Rheuma-tol. 2005;34:114-121.
7. Aringer M, Smolen JS. Cytokine expression in lupus kidneys. Lupus.. 2005;14:13-18.
8. Zampieri S, Alaibac M, Iaccarino L, et al. Tumour necrosis factor alpha is expressed in refractory skin lesions from patients with subacute cutaneous lupus erythematosus. Ann Rheum Dis. 2006;65: 545-548.
9. Soliven B, Wang N. Tumor necrosis factor-alpha regulates nicotinic responses in mixed cultures of sympathetic neurons and nonneuronal cells. J Neurochem. 1995;64:883-894.
10. Jeohn GH, Kong LY, Wilson B, et al. Synergistic neurotoxic effects of combined treatments with cytokines in murine primary mixed neuron/glia cultures. J Neuroimmunol. 1998;85:1-10.
11. Shubayev VI, Myers RR. Axonal transport of TNF-alpha in painful neuropathy: distribution of ligand tracer and TNF receptors. J Neuroimmunol. 2001; 114:48-56.
12. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343: 1594-1602.
13. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet. 2000;356:385-390.
14. van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54:2136-2146.
15. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340:1398-1405.
16. Caroyer JM, Manto MU, Steinfeld SD. Severe sensory neuronopathy responsive to infliximab in primary Sjögren's syndrome. Neurology. 2002;59:1113-1114.
17. Dyck PJ. The clinical heterogeneity of immune sensory and autonomic neuropathies with (or without) sicca. Brain. 2005;128:2480-2482.
18. Chai J, Herrmann DN, Stanton M, et al. Painful small-fiber neuropathy in Sjögren syndrome. Neurology. 2005;65:925-927.
19. Souayah N, Chong PS, Cros D. Acute sensory neuronopathy as the presenting symptom of Sjög-ren's syndrome. J Clin NeuroSci. 2006;13:862-865.
20. Graus F, Pou A, Kanterewicz E, et al. Sensory neuronopathy and Sjögren's syndrome: clinical and immunologic study of two patients. Neurology. 1988;38:1637-1639.
21. Kuntzer T, Antoine JC, Steck AJ. Clinical features and pathophysiological basis of sensory neuropathies (ganglionopathies). Muscle Nerve. 2004;30: 255-268.
22. Huynh C, Ho SL, Fong KY, et al. Peripheral neuropathy in systemic lupus erythematosus. J Clin Neurophysiol. 1999;16:164-168.
23. Omdal R, Mellgren SI, Goøransson L, et al. Small nerve fiber involvement in systemic lupus erythematosus: a controlled study. Arthritis Rheum. 2002;46:1228-1232.
24. Chaudhuri KR, Taylor IK, Niven RM, et al. A case of systemic lupus erythematosus presenting as Guillain-Barré syndrome. Br J Rheumatol. 1989;28: 440-442.
25. Vina ER, Fang AJ, Wallace DJ, et al. Chronic inflammatory demyelinating polyneuropathy in patients with systemic lupus erythematosus: prognosis and outcome. Semin Arthritis Rheum. 2005; 35:175-184.
26. Martinez-Taboada VM, Alonso RB, Armona J, et al. Mononeuritis multiplex in systemic lupus erythema-tosus: response to pulse intravenous cyclophospha-mide. Lupus. 1996;5:74-76.
27. Bharadwaj A, Shenoy D, Aggarwal A. Polyradiculop-athy in a patient of systemic lupus erythematosus. J Assoc Physicians India. 2003;51:304-305.
28. Salama B, Gicquel JJ, Lenoble P, et al. Optic neuropathy in refractory neurosarcoidosis treated with TNF-alpha antagonist. Can J Ophthalmol. 2006;41:766-768.
29. Hoitsma E, Faber CG, van Santen-Hoeufft M, et al. Improvement of small fiber neuropathy in a sarcoid-osis patient after treatment with infliximab. Sarcoid-osis Vasc Diffuse Lung Dis. 2006;23:73-77.
30. Richter C, Wanke L, Steinmetz J, et al. Mononeuritis secondary to rheumatoid arthritis responds to etanercept. Rheumatology. 2000;39:1436-1437.
31. Armstrong DJ, McCarron MT, Wright GD. Successful treatment of rheumatoid vasculitis-associated foot-drop with infliximab. J Rheumatol. 2005;32:759.
32. Garcia-Porrua C, González-Gay MA. Successful treatment of refractory mononeuritis multiplex secondary to rheumatoid arthritis with the anti-tumour necrosis factor alpha monoclonal antibody inflixi-mab. Rheumatology. 2002;41:234-235.
33. Chin RL, Sherman WH, Sander HW, et al. Etanercept (Enbrel) therapy for chronic inflammatory demye-linating polyneuropathy. J Neurol Sci. 2003;210: 19-21.
34. Wang Y, Zhou D, Shen Q, et al. Lipopolysaccharide-induced upregulation of tumor necrosis factor-alpha (TNF-alpha) and TNF receptors in rat sciatic nerve. J Mol NeuroSci. 2007;32:207-216.
35. Sommer C, Lindenlaub T, Teuteberg P, et al. Anti-TNF-neutralizing antibodies reduced pain-related behavior in two different mouse models of painful mononeuropathy. Brain Res. 2001;913:86-89.
36. Sommer C, Schäfers M, Marziniak M, et al. Etaner-cept reduces hyperalgesia in experimental painful neuropathy. J Peripher Nerv Syst. 2001;6:67-72.
37. Wagner R, Myers RR. Endoneurial injection of TNF-alpha produces neuropathic pain behaviors. Neuro-report. 1996;7:2897-2901.
38. Ohtori S, Takahashi K, Moriya H, et al. TNF-alpha and TNF-alpha receptor type 1 upregulation in glia and neurons after peripheral nerve injury: studies in murine DRG and spinal cord. Spine. 2004;29:1082-1088.
39. Schäfers M, Geis C, Svensson CI, et al. Selective increase of tumour necrosis factor-alpha in injured and spared myelinated primary afferents after chronic constrictive injury of rat sciatic nerve. Eur J NeuroSci. 2003;17:791-804.
40. Xu JT, Xin WJ, Zang Y, et al. The role of tumor necrosis factor-alpha in the neuropathic pain induced by Lumbar 5 ventral root transection in rat. Pain. 2006;123:306-321.
41. Wei XH, Zang Y, Wu CY, et al. Peri-sciatic administration of recombinant rat TNFa induces mechanical allodynia via upregulation of TNFa in dorsal root ganglia and in spinal dorsal horn: the role of NF-kappa B pathway. Exp Neurol. 2007;205:471-484.
42. Keswani SC, Polley M, Pardo CA, et al. Schwann cell chemokine receptors mediate HIV-1 gp120 toxicity to sensory neurons. Ann Neurol. 2003;54:287-296.
43. Aringer M, Smolen JS. Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention. Lupus. 2004;13:344-347.
44. Charles PJ, Smeenk RJ, De Jong J, et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. 2000;43:2383-2390.
45. Aringer M, Graninger WB, Steiner G, et al. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum. 2004;50:3161-3169.
46. Hayat SJ, Uppal SS, Narayanan Nampoory MR, et al. Safety and efficacy of infliximab in a patient with active WHO class IV lupus nephritis. Clin Rheuma-tol. 2007;26:973-975.
47. Micheloud D, Nuno L, Rodriguez-Mahou M, et al. Efficacy and safety of etanercept, high-dose intravenous gammaglobulin and plasmapheresis combined therapy for lupus diffuse proliferative nephritis complicating pregnancy. Lupus. 2006;15:881-885.
48. Stübgen JP. Tumor necrosis factor-alpha antagonists and neuropathy. Muscle Nerve. 2008;37:281-292.
49. Mohan N, Edwards ET, Cupps TR, et al. Demyelin-ation occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001;44:2862-2869.
50. Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology. 2001; 57:1885-1888.